A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.
The Weekly Roundup: July 22-26
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Emerging Therapeutic for Non-Segmental Vitiligo: Merck’s MK-6194
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Study Highlights Efficacy of Lotion with Biotechnological Phytocomplex, Niacinamide, and Succinic Acid in Enhancing Microbiota Diversity and Reducing Acne Severity
The FDA Approves Deuruxolitinib for Severe Alopecia in Adults